732978-38-0 Usage
Description
4-[5-(piperidin-4-yl)-1,3,4-oxadiazol-2-yl]pyridine, also known as TAK-831, is a chemical compound belonging to the class of oxadiazole compounds. It features a pyridine ring linked to an oxadiazole ring through a piperidine group, indicating potential as a drug candidate for the treatment of various diseases.
Uses
Used in Pharmaceutical Applications:
4-[5-(piperidin-4-yl)-1,3,4-oxadiazol-2-yl]pyridine is used as a potential drug candidate for the treatment of various diseases due to its unique chemical structure and the diverse biological activities of oxadiazole compounds, which include antimicrobial, antiviral, and antitumor properties.
Further research and studies are needed to fully understand the pharmacological profile and potential therapeutic uses of TAK-831 in different medical fields.
Check Digit Verification of cas no
The CAS Registry Mumber 732978-38-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 7,3,2,9,7 and 8 respectively; the second part has 2 digits, 3 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 732978-38:
(8*7)+(7*3)+(6*2)+(5*9)+(4*7)+(3*8)+(2*3)+(1*8)=200
200 % 10 = 0
So 732978-38-0 is a valid CAS Registry Number.
732978-38-0Relevant articles and documents
Discovery of highly potent triazole antifungal agents with piperidine-oxadiazole side chains
He, Xiaomeng,Jiang, Yan,Zhang, Yongqiang,Wu, Shanchao,Dong, Guoqiang,Liu, Na,Liu, Yang,Yao, Jianzhong,Miao, Zhenyuan,Wang, Yan,Zhang, Wannian,Sheng, Chunquan
, p. 653 - 664 (2015/04/27)
Due to increasing incidence and mortality of invasive fungal infections, discovery and development of new generations of antifungal agents represents a challenging task. On the basis of our previously reported triazole-benzyloxypiperidinyl lead compound, a series of novel triazole antifungal agents containing piperidine-oxadiazole side chains were rationally designed and synthesized. Most of the target compounds showed excellent inhibitory activity against clinically important fungal pathogens. In particular, compounds 6g (MIC = 0.031 μg mL-1) and 11b (MIC = 0.016 μg mL-1) were highly active against Candida albicans including fluconazole-resistant strains. Moreover, they showed inhibitory activity against hyphal formation with low toxicity, which were promising leads for further development. This journal is
